Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a ‘
- C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide in patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one single stranded antisense oligonucleotide 15 to 30 nucleotides in length or a double stranded oligonucleotide 19-30 nucleotides in length wherein at least one strand of said at least one oligonucleotide leas at least 80% sequence identity to a reverse complement of a polynucleotide comprising 15 to 30 or 19-30 consecutive nucleotides within nucleotides 1 to 2074 of SEQ ID NO;
2 and 1 to 1237 of SEQ ID NO;
3;
thereby upregulating a function of and/or the expression of the ‘
C terminus of HSP70-Interading Protein’
(CHIP) polynucleotide in patient cells or tissues in vivo or in vitro.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.
-
Citations
16 Claims
-
1. A method of upregulating a function of and/or the expression of a ‘
- C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide in patient cells or tissues in vivo or in vitro comprising;contacting said cells or tissues with at least one single stranded antisense oligonucleotide 15 to 30 nucleotides in length or a double stranded oligonucleotide 19-30 nucleotides in length wherein at least one strand of said at least one oligonucleotide leas at least 80% sequence identity to a reverse complement of a polynucleotide comprising 15 to 30 or 19-30 consecutive nucleotides within nucleotides 1 to 2074 of SEQ ID NO;
2 and 1 to 1237 of SEQ ID NO;
3;
thereby upregulating a function of and/or the expression of the ‘
C terminus of HSP70-Interading Protein’
(CHIP) polynucleotide in patient cells or tissues in vivo or in vitro. - View Dependent Claims (12)
- C terminus of HSP70-Interacting Protein’
-
2. A method of upregulatin a function of and/or the expression of a ‘
- C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide in patient cells or tissues in vivo or in vitro comprising;contacting said cells or tissues with at least one antisense oligonucleotide 15 to 30 nucleotides in length or a double stranded oligonucleotide 19-30 nucleotides in length wherein at least one strand of the at least one oligonucleotide has at least 80% sequence identity to a 15-30nucleotide region or a 19-30 nucleotide region of a natural antisense polynucleotide of a ‘
C terminus of HSP70-Interacting Protein’
(CHF) polynucleotide;
thereby upregulating a function of and/or the expression of the ‘
C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide in patient cells or tissues in vivo or in vitro.
- C terminus of HSP70-Interacting Protein’
-
3. A method of upregulating a function of and/or the expression of a ‘
- C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide in patient cells or tissues in vivo or in vitro comprising;contacting said cells or tissues with at least one single stranded antisense oligonucleotide of 15 to 30 nucleotides in length that targets a complementary region of a natural antisense polynucleotide of the ‘
C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide having SEQ ID NO;
2 or 3;
thereby upregulating a function, of and/or the expression of the ‘
C terminus of HSP70-interacting Protein’
(CHIP) polynucleotide in patient cells or tissues in vivo or in vitro. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11)
- C terminus of HSP70-Interacting Protein’
-
13. A method of upregulating a function of and/or the expression of a ‘
- C terminus of HSP70-Interacting Protein’
(CHIP) gene in mammalian cells or tissues in vivo or in vitro comprising;contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for an antisense polynucleotide of a ‘
C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide having SEQ ID NOS;
2 or 3; and
, upregulating a function of and/or the expression of ‘
C terminus of HSP70-Interacting Protein’
(CHIP) in mammalian cells or tissues in vivo or in vitro. - View Dependent Claims (14)
- C terminus of HSP70-Interacting Protein’
-
15. A method of upregulating a function of and/or the expression, of ‘
- C terminus Of HSP70-Interacting Protein’
(CHIP) or CHIP gene in mammalian cells or tissues in vivo or in vitro comprising;contacting said cells or tissues with at least one antisense oligonucleotide of about 10 to 30 nucleotides in length specific for noncoding and/or coding sequences of a natural antisense strand of a ‘
C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide having SEQ ID NOS;
2 or 3; and
, upregulating the function and/or expression of the ‘
C terminus of HSP70-Interacting Protein’
(CHIP) in mammalian cells or tissues in vivo or in vitro.
- C terminus Of HSP70-Interacting Protein’
-
16. A method of preventing or treating a disease associated with at least one ‘
- C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide and/or at least one encoded product thereof, comprising;administering to a patient a therapeutically effective dose of at least one antisense oligonucicotide of 15 to 30 nucleotides in length that specifically binds to a natural antisense polynucleotide of said at least one ‘
C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide having SEQ ID NOS;
2 or 3 and upregulates_ expression of said at least one ‘
C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide;
thereby treating the disease associated with the at least one ‘
C terminus of HSP70-Interacting Protein’
(CHIP) polynucleotide and/or at least one encoded product thereof wherein the disease is cancer.
- C terminus of HSP70-Interacting Protein’
Specification